For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

Novo Nordisk chief executive Lars Fruergaard Jørgensen faced questioning on Capitol Hill over the health care costs of the ...

Ozempic and Wegovy are some of the most popular drugs in the country, driven by their remarkable success in treating diabetes ...

Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday ...

Novo Nordisk CEO commits to exploring ways to make weight-loss drugs more affordable for U.S. patients after hearing from ...

Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to ...

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Novo Nordisk Chief Executive Lars Jorgensen challenged Medicare's new role negotiating prescription drug prices during his testimony before a Senate committee on the company's blockbuster diabetes and ...

No, if Novo Nordisk lowered their list price for Ozempic and Wegovy tomorrow to a price that was the same or lower than current net cost, that change by itself would not result in less favorable ...

Some people may be eligible for Medicare coverage for Wegovy if they meet medical criteria for heart disease risk. However, Medicare does not cover medications that are strictly for weight management.